The trial is expected to generate significant clinical data by late summer 2026. Allarity plans to pursue multiple advantaged ...

June 4, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...

Tarpon Springs, Florida Wednesday, June 4, 2025, 12:00 Hrs [IST] ...

Allarity Therapeutics ( ($ALLR) ) has shared an update. On June 2, 2025, Allarity Therapeutics announced the enrollment of the first patient in ...

Stenoparib is an orally available small-molecule drug that inhibits both PARP1/2 and tankyrase1/2, targeting DNA repair and the WNT signaling pathway—key drivers in treatment resistance and ...

June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...

Allarity Therapeutics, Inc. announced that it has enrolled the first patient in a new Phase 2 clinical trial for stenoparib, a dual PARP and WNT pathway inhibitor, aimed at treating advanced ...